Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 1-8

  Keshelava, Nino ^a,b   Groshen, Susan ^b   Reynolds, C Patrick ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bone marrow transplantation; CPT 11; Etoposide; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; IRINOTECAN; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0033951987     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006736     Document Type: Article

References (38)

1. 1. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37: 195
2. 2. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47: 1952
3. 3. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM (1996) Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78: 527
4. 4. Boos J, Krumpelmann S, Schulze Westhoff P, Euting T, Berthold F, Jurgens H (1995) Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 13: 2954
5. 5. Chatterjee S, Cheng MF, Berger NA (1990) Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun 2: 401
6. 6. Chou J, Chou T (1987) Multiple drug-effect analysis (program B). In: Chou J, Chou TCh (eds) Dose-effect analysis with microcomputers. Memorial Sloan-Kettering Cancer Center, New York, pp 19-64
7. 7. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709
8. 8. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163
9. 9. D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Pisoni MB, Piazza E, Beer M, Cavalli F (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7: 141
10. 10. Frgala T, Proffitt RT (1995) A novel 96-well plate cytotoxicity assay based on fluorescence digital imaging microscopy. Proc Am Assoc Cancer Res 36: 303
11. 11. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171
12. 12. Houghton PJ, Cheshire PJ, Hallman JD 2nd, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393
13. 13. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873
14. 14. Keshelava N, Seeger RC, Reynolds CP (1997) Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer 33: 2002
15. 15. Keshelava N, Seeger RC, Groshen S, Reynolds CP (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396
16. 16. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351
17. 17. Lynch TJ Jr, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E 3rd (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12: 347
18. 18. Mattano LA Jr, Moss TJ, Emerson SG (1992) Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 52: 4701
19. 19. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP (1999) Improved outcome for high risk neuroblastoma with high dose therapy and purged autologous bone marrow transplantation and with subsequent 13-cis-retinoic acid. New Eng J Med (in press)
20. 20. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K (1995) Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 75: 2757
21. 21. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164
22. 22. O'Reilly S, Donehower RC, Rowinsky EK, Ord S, Grochow LB (1996) A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 7: 410
23. 23. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP3, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK (1997) Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 15: 177
24. 24. Paul KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 108
25. 25. Perez Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK (1996) Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14: 2785
26. 26. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12: 539
27. 27. Proffitt RT, Tran JV, Reynolds CP (1996) A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 24: 204
28. 28. Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ (1995) Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 13: 163
29. 29. Reynolds CP, Villablanca JG, Stram DO, Harris R, Seeger RC, Matthay KK (1998) 13-Cis-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol 17: 2
30. 30. Robert F, Soong SJ, Wheeler RH (1997) A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol 20: 298
31. 31. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH (1992) Phase I and pharmacologic study of toptecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647
32. 32. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC (1996) Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group Studies. J Clin Oncol 14: 2417
33. 33. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962
34. 34. Wang YL, Einhorn P, Reynolds CP (1998) Expression of the neuronal marker PGP9.5 in cell lines from neuroblastoma, primitive neuroectodermal tumor, and Ewing's sarcoma. Proc Am Assoc Cancer Res 37: 203
35. 35. Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA (1997) Toptecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57: 1425
36. 36. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna S, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ (1998) Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4: 743
37. 37. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ (1998) Relationship between toptecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90: 505
38. 38. Zar JH (1974) Simple linear correlation. In: Biostatistical analysis. Prentice-Hall, Englewood Cliffs, pp 236-243